SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Trillium Therapeutics Inc. – ‘20FR12B’ on 8/12/14 – EX-1.6

On:  Tuesday, 8/12/14, at 5:04pm ET   ·   Accession #:  1062993-14-4759   ·   File #:  1-36596

Previous ‘20FR12B’:  None   ·   Next:  ‘20FR12B/A’ on 10/3/14   ·   Latest:  ‘20FR12B/A’ on 11/26/14   ·   7 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 8/12/14  Trillium Therapeutics Inc.        20FR12B               19:4.1M                                   Newsfile Corp/FA

Registration of Securities of a Foreign Private Issuer   —   Form 20-F
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 20FR12B     Registration of Securities of a Foreign Private     HTML   1.70M 
                          Issuer -- form20fr12b                                  
 2: EX-1.1      Underwriting Agreement -- exhibit1-1                HTML     24K 
 3: EX-1.2      Underwriting Agreement -- exhibit1-2                HTML     20K 
 4: EX-1.3      Underwriting Agreement -- exhibit1-3                HTML     15K 
 5: EX-1.4      Underwriting Agreement -- exhibit1-4                HTML     38K 
 6: EX-1.5      Underwriting Agreement -- exhibit1-5                HTML     49K 
 7: EX-1.6      Underwriting Agreement -- exhibit1-6                HTML    119K 
 8: EX-1.7      Underwriting Agreement -- exhibit1-7                HTML     81K 
 9: EX-2.1      Plan of Acquisition, Reorganization, Arrangement,   HTML    246K 
                          Liquidation or Succession -- exhibit2-1                
10: EX-4.1      Instrument Defining the Rights of Security Holders  HTML    118K 
                          -- exhibit4-1                                          
17: EX-4.10     Instrument Defining the Rights of Security Holders  HTML    241K 
                          -- exhibit4-10                                         
11: EX-4.2      Instrument Defining the Rights of Security Holders  HTML    397K 
                          -- exhibit4-2                                          
12: EX-4.5      Instrument Defining the Rights of Security Holders  HTML     40K 
                          -- exhibit4-5                                          
13: EX-4.6      Instrument Defining the Rights of Security Holders  HTML     38K 
                          -- exhibit4-6                                          
14: EX-4.7      Instrument Defining the Rights of Security Holders  HTML    328K 
                          -- exhibit4-7                                          
15: EX-4.8      Instrument Defining the Rights of Security Holders  HTML    337K 
                          -- exhibit4-8                                          
16: EX-4.9      Instrument Defining the Rights of Security Holders  HTML    289K 
                          -- exhibit4-9                                          
18: EX-15.1     Letter re: Unaudited Interim Financial Information  HTML     10K 
                          -- exhibit15-1                                         
19: EX-15.2     Letter re: Unaudited Interim Financial Information  HTML      9K 
                          -- exhibit15-2                                         


EX-1.6   —   Underwriting Agreement — exhibit1-6


This exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



  Trillium Therapeutics Inc.: Exhibit 1.6 - Filed by newsfilecorp.com  

Exhibit 1.6

Ontario Corporation Number
Numéro de la société en Ontario
1916667








 

  ARTICLES OF AMALGAMATION
Form 4 STATUTS DE FUSION
Business    
Corporations 1. The name of the corporation is: (Set out in BLOCK CAPITAL LETTERS)
Act   Dénomination sociale de la société: (Écrire en LETTRES MAJUSCULES SEULEMENT):
             
Formule 4   TRILLIUM THERAPEUTICS INC
Loi sur les    
sociétés parés par    
actions    
  2. The address of the registered office is:
    Adresse du siège social en :
     
    96 Skyway Avenue,
    Street & Number or R.R. Number & if Multi-Office Building give Room No. /
    Rue et numéro ou numéro de la R.R. et, s’il s’agit d’un édifice á bureaux, numéro du bureau
         
    Toronto ONTARIO M 9 W 4 Y 9
    Name of Municipality or Post Office /   Postal Code/Code postal
    Nom de la municipalité ou du bureau de poste    
               
  3. Number of directors is/are:
Nombre d’administrateurs:
Fixed number
Nombre fixe
  OR minimum and maximum
OU minimum et maximum
3 10
         
  4. The director(s) is/are:/ Administrateur(s):    
    First name, middle names and surname
Prénom, autres prénoms et nom de famille
Address for service, giving Street & No. or R.R. No., Municipality, Province, Country and Postal Code
Domicile élu, y compris la rue et le numéro ou le numéro de la
R.R., le nom de la municipalité, la province, le pays et le code postal
Resident Canadian
State ‘Yes’ or ‘No’
Résident canadien

Oui/Non
         
    Luke Beshar 96 Skyway Avenue, Toronto, Ontario,
Canada M9W 4Y9
No
         
    Henry Friesen 96 Skyway Avenue, Toronto, Ontario,
Canada M9W 4Y9
Yes
         
    Robert Kirkman 96 Skyway Avenue, Toronto, Ontario,
Canada M9W 4Y9
No
         

Page 1 of/de 6



        Annex / Annexe
         
  4. The director(s) is/are:   1A
    Administrateur(s)    
First name, middle names and surname
Prénom, autres prénoms et nom de famille
Address for service, giving Street & No. or R.R. No., Municipality, Province, Country and Postal Code
Domicile élu, y compris la rue et le numéro ou le numéro de la R.R., le nom de la municipalité, la province, le pays et le code postal
Resident Canadian
State ‘Yes’ or ‘No’
Résident canadien
Oui/Non
         
Calvin Stiller 96 Skyway Avenue, Toronto, Ontario,
Canada M9W 4Y9
Yes
         
Michael Moore 96 Skyway Avenue, Toronto, Ontario,
Canada M9W 4Y9
No
         
Thomas Reynolds 96 Skyway Avenue, Toronto, Ontario,
Canada M9W 4Y9
No
         
Niclas Stiernholm 96 Skyway Avenue, Toronto, Ontario,
Canada M9W 4Y9
Yes



  5 Method of amalgamation, check A or B
    Méthode choisie pour la fusion – Cocher A ou B:
      A - Amalgamation Agreement / Convention de fusion :
         
    [   ]   The amalgamation agreement has been duly adopted by the shareholders of each of the amalgamating corporations as required by subsection 176 (4) of the Business Corporations Act on the date set out below.
        Les actionnaires de chaque société qui fusionne ont dûment adopté la convention de fusion conformément au paragraphe 176(4) de la Loi sur les sociétés par actions à la date mentionnée ci-dessous.
    or    
    ou    
      B - Amalgamation of a holding corporation and one or more of its subsidiaries or amalgamation of subsidiaries / Fusion d’une société mère avec une ou plusieurs de ses fillales ou fusion de fillales :
         
    [X]   The amalgamation has been approved by the directors of each amalgamating corporation by a resolution as required by section 177 of the Business Corporations Act on the date set out below.
        Les administrateurs de chaque société qui fusionne ont approuvé la fusion par voie de résolution conformément à l’article 177 de la Loi sur les sociétés par actions à la date mentionnée ci-dessous.
         
        The articles of amalgamation in substance contain the provisions of the articles of incorporation of
        Les statuts de fusion reprennent essentiellement les dispositions des statuts constitutifs de
         
        Stem Cell Therapeutics Corp.
        and are more particularly set out in these articles.
        et sont énoncés textuellement aux présents statuts.
         
    Names of amalgamating corporations Ontario Corporation Number Date of Adoption/Approval
    Dénomination sociale de sociétés qui fusionnent Numéro de société en Ontario Date d’adoption ou d’approbation
        Year Month Day
        Année Mois jour
             
    Stem Cell Therapeutics Corp. 1892251 2014-05-27
             
             
    Trillium Therapeutics Inc. 1893906 2014-05-27


Page 2 of/de 6

  6. Restrictions, if any, on business the corporation may carry on or on powers the corporation may exercise.
    Limites, s’il y a lieu, imposées aux activités commerciales ou aux pouvoirs de la société.
     
    None
     
  7. The classes and any maximum number of shares that the corporation is authorized to issue:
    Catégories et nombre maximal, s’il y a lieu, d’actions que la société est autorisée à émettre :
     
    an unlimited number of Common shares;
    an unlimited number of Class B shares;
    an unlimited number of First Preferred shares; and
    an unlimited number of Series I Non-Voting Convertible First Preferred shares.


 Page 3 of/de 6

8 Rights, privileges: restrictions and conditions (if any) attaching to each class of shares and directors authority with respect to any class of shares which may be issued in series:
Droits, privilèges, restrictions et conditions, s’il y a lieu, rattachés à chaque catégorie d’actions et pouvoirs des administrateurs relatifs à chaque catégorie d’actions qui peut être émise en série:
     
    See pages 4a – 4k


4a

1.             The rights, privileges, restrictions and conditions attaching to the Common shares are as follows:

(a)

Voting Rights:

The holders of the Common shares shall be entitled to receive notice of and to attend all annual and special meetings of the shareholders of the Corporation and to one vote in respect of each Common share held at all such meetings.

(b)

Payment of Dividends:

The holders of the Common shares shall be entitled to receive dividends if, as and when declared by the board of directors of the Corporation out of the assets of the Corporation properly applicable to the payment of dividends in such amounts and payable in such manner as the board of directors may from time to time determine. Subject to the rights of the holders of any other class of shares of the Corporation entitled to receive dividends in priority to or concurrently with the holders of the Common shares, the board of directors may in its sole discretion declare dividends on the Common shares to the exclusion of any other class of shares of the Corporation.

(c)

Participation upon Liquidation, Dissolution or Winding Up:

In the event of the liquidation, dissolution or winding up of the Corporation or other distribution of assets of the Corporation among its shareholders for the purpose of winding up its affairs, the holders of the Common shares shall, subject to the rights of the holders of any other class of shares of the Corporation entitled to receive assets of the Corporation upon such a distribution in priority to or concurrently with the holders of the Common shares, be entitled to participate in the distribution. Such distribution shall be made in equal amounts per share on all the Common shares at the time outstanding without preference or distinction.

2.             The rights, privileges, restrictions and conditions attaching to the Class B shares are as follows:

(a)

Voting Rights:

The holders of the Class B shares shall be entitled to receive notice of and to attend any meeting of the shareholders of the Corporation but shall not be entitled to vote any of their Class B shares at any such meeting.

(b)

Participation upon Liquidation, Dissolution or Winding Up:

In the event of the liquidation, dissolution or winding up of the Corporation or other distribution of assets of the Corporation among its shareholders for the purpose of winding up its affairs, the holders of the Class B shares shall, subject to the rights of the holders of any other class of shares of the Corporation entitled to receive assets of the Corporation upon such a distribution in priority to the Class B shares, be entitled to participate rateably with the Common shares in any distribution of the assets of the Corporation.


 4b

(c)

Conversion At Holders’ Option:

     
(1)

Each issued and fully paid Class B share may at any time be converted, at the option of the holder, into one Common share. The conversion privilege herein provided for may be exercised by notice in writing given to the Corporation accompanied by a certificate or certificates representing the Class B shares in respect of which the holder thereof desires to exercise such right of conversion and such notice shall be signed by the person registered on the books of the Corporation as the holder of the Class B shares in respect of which such right is being exercised or by his duly authorized attorney and shall specify the number of Class B shares which the holder desires to have converted. The holder shall also pay any governmental or other tax imposed in respect of such transaction. Upon receipt of such notice the Corporation shall issue certificates representing fully paid Common shares upon the basis above prescribed and in accordance with the provisions hereof to the registered holder of the Class B shares represented by the certificate or certificates accompanying such notice. If less than all of the Class B shares represented by any certificate are to be converted, the holder shall be entitled to receive a new certificate for the Class B shares representing the shares comprised in the original certificates which are not to be converted.

     
(2)

Idem: All Common shares resulting from any conversion of issued and fully paid Class B shares into Common shares pursuant to clause 2(c)(1) hereof shall be deemed to be fully paid and non-assessable.

     
(3)

Idem: None of the Class B shares or the Common shares shall be subdivided, consolidated, reclassified or otherwise changed unless contemporaneously therewith the other said class of shares is subdivided, consolidated, reclassified or otherwise changed in the same proportion and in the same manner.

3.             The rights, privileges, restrictions and conditions attaching to the First Preferred shares are as follows:

(a)

Series:

The First Preferred shares may at any time and from time to time be issued in one or more series. Subject to the provisions of clauses 3(b) and (c), the board of directors of the Corporation may from time to time before the issue thereof fix the number of shares in, and determine the designation, rights, privileges, restrictions and conditions attaching to the shares of, each series of First Preferred shares.

(b)

Idem:

The First Preferred shares shall be entitled to priority over the Common shares and Class B shares and all other shares ranking junior to the First Preferred shares with respect to the payment of dividends and the distribution of assets of the Corporation in the event of any liquidation, dissolution or winding up of the Corporation or other distribution of assets of the Corporation among its shareholders for the purpose of winding up its affairs.


 4c

(c)

Idem:

The First Preferred shares of each series shall rank on a parity with the First Preferred shares of every other series with respect to priority in the payment of dividends and in the distribution of assets of the Corporation in the event of any liquidation, dissolution or winding up of the Corporation or other distribution of assets of the Corporation among its shareholders for the purpose of winding up its affairs.

4.             The rights, privileges, restrictions and conditions attaching to the Series I Non-Voting Convertible First Preferred shares are as follows:

(a)

Voting Rights:

     
(1)

The holders of Series I Non-Voting Convertible First Preferred shares shall be entitled to receive notice of and to attend at any meeting of the shareholders of the Corporation but shall not be entitled to vote at any such meeting, except with respect to such matters and in the manner as to which voting rights are accorded to the holders of specified classes of shares pursuant to the provisions of the Business Corporations Act (Ontario) or applicable law (the “Exception”).

     
(2)

In the event of an Exception, and to the extent permitted by law, a holder of Series I Non-Voting Convertible First Preferred shares shall: (A) vote together with the holders of Common shares as a single class; and (B) be entitled to cast that number of votes equal to the number of whole Common shares into which the Series I Non-Voting Convertible First Preferred shares held by such holder are convertible as of the record date for determining shareholders entitled to vote on such matters.

     
(b)

Dividends:

The holders of the Series I Non-Voting Convertible First Preferred shares shall be entitled to receive and the Corporation shall pay thereon, dividends if, as and when declared by the board of directors of the Corporation out of the assets of the Corporation properly applicable to the payment of dividends in such amounts and payable in such manner (and whether in money or otherwise) as the board of directors may from time to time determine, equally, on a share-for-share basis, with the holders of other series of First Preferred shares and, at the discretion of the board of directors, either in priority to, or equally on a share-for-share basis with, the holders of Common shares and Class B shares.

(c)

Liquidation, Dissolution and Winding-up Rights:

In the event of liquidation, dissolution or winding-up of the affairs of the Corporation, whether voluntary or involuntary, or in the event of any other distribution of assets of the Corporation among its shareholders for the purpose of winding up its affairs, or in the event of a reduction or redemption of the capital stock of the Corporation, the holders of the Series I Non-Voting Convertible First Preferred shares shall be entitled to receive an amount per share equal to that amount of money that was received by the Corporation as consideration for such Series I Non-Voting Convertible First Preferred shares or in the event that Series I Non-Voting Convertible First Preferred shares were not issued for money, then the amount equal to the fair value of any property received by the Corporation as consideration for the issuance of such Series I Non-Voting Convertible First Preferred shares (where such fair value is determined at the time of the issuance of the Series I Non-Voting Convertible First Preferred shares) divided by the number of Series I Non-Voting Convertible First Preferred shares issued, in lawful money of Canada, the whole before any amount shall be paid by the Corporation or any assets of the Corporation shall be distributed to holders of Common shares and Class B shares. After payment to the holders of the Series I Non-Voting Convertible First Preferred shares of the amount so payable to them in accordance with this Section, they shall not be entitled to share in any further distribution of property or assets of the Corporation.


 4d

(d)

Authority to Issue Series I Non-Voting Convertible First Preferred shares:

The board of directors of the Corporation may from time to time authorize the issuance of the Series I Non-Voting Convertible First Preferred shares and fix the number of Series I Non-Voting Convertible First Preferred shares to be allotted and issued and the amount and kind of consideration to be received by the Corporation in respect of each such issuance of Series I Non-Voting Convertible First Preferred shares.

(e)

Reservation of Common shares Issuable Upon Conversion:

The Corporation shall at all times reserve and keep available out of its authorized and unissued Common shares for the sole purpose of issuance upon conversion of the Series I Non-Voting Convertible First Preferred shares, free from pre-emptive rights or any other actual contingent purchase rights of Persons other than the holders of the Series I Non-Voting Convertible First Preferred shares, not less than such aggregate number of Common shares as shall be issuable (taking into account the adjustments of Section 4(f)(5)) upon the conversion of all outstanding Series I Non-Voting Convertible First Preferred shares. All Common shares that shall be so issuable shall, upon issue, be duly authorized, validly issued, fully paid and non-assessable.

(f)

Conversion:

     
(1)

Interpretation:

In this Section 4(f), the following terms shall have the following respective meanings:

“Alternate Consideration” has the meaning given to it in Section 4(f)(5)(c);

“CDS” means the CDS Clearing and Depository Services Inc. and its successors;

“CDS Participant” means a broker, dealer, bank, other financial institution or other person who, directly or indirectly, from time to time, effects book-based transfers with CDS and pledges of securities deposited with CDS;

“Conversion Date” means the date as of which the subject Series I Non-Voting Convertible First Preferred shares are to be converted;


4e

“Conversion Price” means Cdn.$0.21, subject to adjustment in accordance with Section 4(f)(5);

“Conversion Ratio” means, for each Series I Non-Voting Convertible First Preferred share, an amount equal to the Reference Price divided by the Conversion Price;

“Exchange” means the TSX Venture Exchange or, if applicable, such other stock exchange on which the Common shares are principally traded;

“Fundamental Transaction” has the meaning given to it in Section 4(f)(5)(c);

“Notice of Conversion” means a notice of conversion of Series I Non-Voting Convertible First Preferred shares given by a holder of such shares or by the Corporation;

“Person” means an individual, partnership, corporation, trust, unincorporated association, joint venture or other entity and includes a group of Persons acting jointly or in concert;

“Reference Price” means Cdn.$0.21; and

“Underlying shares” means, in respect of Series I Non-Voting Convertible First Preferred shares to be converted, the Common shares to be issued upon such conversion.

  (2)

Conversion Rights of Holders: Each holder of Series I Non-Voting Convertible First Preferred shares shall have the right to convert all or any of the holder’s Series I Non-Voting Convertible First Preferred shares into that number of Common shares equal to the Conversion Ratio in effect at the time of such conversion.

         
  (3)

Notice of Conversion:

         
a.

A Notice of Conversion by a holder of Series I Non-Voting Convertible First Preferred shares to the Corporation must be given not less than seven (7) calendar days prior to the Conversion Date.

         
  b.

A Notice of Conversion shall be in writing and shall be validly and effectively given on the date on which it is received, if delivered personally, or sent, if sent by fax or email to the Corporation.

         
  c.

A Notice of Conversion given by a holder of Series I Non-Voting Convertible First Preferred shares to the Corporation shall set out:

         

i.
the Conversion Date which shall be specified by the holder;
         
ii. unless all the Series I Non-Voting Convertible First Preferred shares held by the holder who delivered the Notice of Conversion are to be converted (which, if such is the case, shall be stated in the notice), the number of Series I Non-Voting Convertible First Preferred shares which are to be converted; and


 4f

 

iii.

the representation that the Underlying shares will be registered in the name of the registered holder of the Series I Non-Voting Convertible First Preferred shares to be converted unless, alternatively, subject to applicable securities laws and restrictions on transfer, including, if applicable, United States securities laws, the transfer agent of the Corporation (the Transfer Agent) receives from such holder, on or before the seventh calendar day prior to the Conversion Date, at the principal transfer office of the Transfer Agent in the City of Toronto, written notice in a form and executed in a manner satisfactory to the Transfer Agent directing the Corporation to register the Underlying shares in some other name or names (the Transferee(s)) and stating the name(s) (with address(es)) accompanied by payment by the holders to the Transfer Agent of any transfer tax that may be payable by reason thereof and a written declaration of such matters as may be required by law in order to determine the entitlement of the Transferees to be transferred or hold the Underlying shares.

         
  (4)

Delivery of Share Certificates / Recording of Beneficial Interest upon Conversion:

         
  a.

On the Conversion Date, a holder of Series I Non-Voting Convertible First Preferred shares shall receive, upon surrender for cancellation of the certificate or certificates representing the Series I Non-Voting Convertible First Preferred shares, a certificate evidencing the Underlying shares issuable to such holder in accordance with this Section 4(f), which Underlying shares so issued shall be listed on the Exchange. Alternatively, subject to applicable securities laws, including, if applicable, United States securities laws, such holder may request, in the Notice of Conversion or by written request delivered to the Corporation not later than ten calendar days prior to the Conversion Date, that the Corporation record or cause to be recorded, in the book-based system administered by CDS in respect of the Common shares, such holder’s interest in such shares, in which case the Notice of Conversion (or the subsequent written request) shall provide the account particulars of the holder’s CDS Participant and other details necessary to record such interest in the CDS system.

         
  b.

Any Series I Non-Voting Convertible First Preferred shares so converted shall be converted effective on the Conversion Date. From and after the Conversion Date, a holder of Series I Non-Voting Convertible First Preferred shares so converted shall cease to be entitled to exercise any of the rights attributable to such shares (but, for greater certainty, will continue to be entitled to receive dividends on the Series I Non-Voting Convertible First Preferred shares so converted in respect of which the ex-dividend date occurs prior to the Conversion Date but are paid on or after the Conversion Date), and shall become a holder of the Underlying shares of record, effective on the Conversion Date.



  4g

  c.

If less than all of the Series I Non-Voting Convertible First Preferred shares of a holder are converted on any Conversion Date, the Corporation shall issue to such holder on the Conversion Date a new share certificate representing the balance of the Series I Non-Voting Convertible First Preferred shares not converted.

         
  (5)

Certain Adjustments

         
a.

Stock Dividends and Stock Splits. If the Corporation, at any time while any Series I Non-Voting Convertible First Preferred shares are outstanding: (A) pays a stock dividend or otherwise makes a distribution or distributions payable in Common shares (which, for avoidance of doubt, shall not include any Common shares issued by the Corporation upon conversion of Series I Non-Voting Convertible First Preferred shares) with respect to the then outstanding Common shares; (B) subdivides outstanding Common shares into a larger number of shares; or (C) combines (including by way of a reverse stock split) outstanding Common shares into a smaller number of shares, the Conversion Price shall be multiplied by a fraction of which the numerator shall be the number of Common shares (excluding any treasury shares of the Corporation) outstanding immediately before such event and of which the denominator shall be the number of Common shares outstanding immediately after such event. Any adjustment made pursuant to this Section 4(f)(5)(a) shall become effective immediately after the record date for the determination of shareholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision or combination.

         
  b.

Rights Upon Distribution of Assets. If the Corporation shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of Common shares, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, reorganization, plan of arrangement or other similar transaction) (a “Distribution”), a holder of Series I Non-Voting Convertible First Preferred shares shall be entitled to receive the dividend or distribution of assets that would have been payable to such holder pursuant to the Distribution had such holder converted his, her or its Series I Non-Voting Convertible First Preferred shares (or, if he, she or it had partially converted such shares prior to the Distribution, any unconverted portion thereof) immediately prior to such record date.

         
  c.

Fundamental Transaction.

 

 
 

i.

Right to Receive Consideration. If, at any time while any Series I Non-Voting Convertible First Preferred shares are outstanding:



 4h

  (A)

the Corporation effects any amalgamation, merger, business combination or other transaction of the Corporation with another person, other than a wholly-owned subsidiary, or an arrangement pursuant to the Business Corporations Act (Ontario) involving the Corporation or another transaction pursuant to which a Person, or a group of Persons acting jointly or in concert, acquires all of the issued and outstanding Common shares;

     
  (B)

the Corporation effects any sale, lease or other disposition of all or substantially all of the assets or undertaking of the Corporation;

     
  (C)

the Corporation effects any reclassification of Common shares or any compulsory share exchange pursuant (other than as a result of a dividend, subdivision or combination covered by Section 4(f)(5)(a) above) to which the Common shares are effectively converted into or exchanged for other securities, cash or property, or any similar transaction of series of transactions involving the Corporation or any of its subsidiaries, directly or indirectly,

     
 

(in any such case, a “Fundamental Transaction”), then, a holder of Series I Non-Voting Convertible First Preferred shares shall have the right to receive (in exchange for such Series I Non-Voting Convertible First Preferred shares in the event that the Common shares are exchanged for other securities, cash or property in the Fundamental Transaction) the same kind and amount of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of Common shares, assuming conversion of the Series I Non-Voting Convertible First Preferred shares in accordance with Section 4(f)(2) (the “Alternate Consideration”).


  ii.

Alternate Consideration. If holders of Common shares are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the a holder of Series I Non-Voting Convertible First Preferred shares shall be given the same choice as to the Alternate Consideration it receives upon any conversion of Series I Non-Voting Convertible First Preferred shares following such Fundamental Transaction.

     
  iii.

Takeover Bid. In the event of a “takeover bid” that is a “formal bid” (as such terms are defined in the Securities Laws in the Province of Ontario) for the Common shares, the offeror of such bid shall make an offer (the “Preferred Share Offer”) to acquire the same percentage of outstanding Series I Non-Voting Convertible First Preferred shares as the percentage of Common shares for which the formal bid is being made, and such Preferred Share Offer shall be on the same terms and for the same amount and kind of per share consideration that is offered to the holders of Common shares under the formal bid.



4i

  iv.

Successor in Interest. To the extent necessary to effectuate the foregoing provisions, any successor to the Corporation in such Fundamental Transaction shall include in its constating documents shares having the same terms and conditions and issue to the holders of Series I Non-Voting Convertible First Preferred shares new preferred shares consistent with the foregoing provisions and evidencing the such holders’ right to convert such preferred shares into Alternate Consideration.

       
  v.

Ibid. The terms of any agreement to which the Corporation is a party and pursuant to which a Fundamental Transaction is effected shall include terms requiring any such successor to comply with the provisions of this Section 4(f)(5)(c) and ensuring that the Series I Non-Voting Convertible First Preferred shares (or any such replacement security) will be similarly adjusted upon any subsequent transaction analogous to a Fundamental Transaction.

       
  vi.

Notice. The Corporation shall cause to be delivered to each holder, at its last address as it shall appear upon the share register of the Corporation, written notice of any Fundamental Transaction at least 61 days prior to the date on which such Fundamental Transaction is expected to become effective or close.

       
  d.

Notice to the Holders:

       
  i.

Adjustment to Conversion Price. Whenever the Conversion Price is adjusted pursuant to any provision of this Section 4(f), the Corporation shall promptly deliver to each holder of Series I Non-Voting Convertible First Preferred shares a notice setting forth the Conversion Ratio after such adjustment and setting forth a brief statement of the facts requiring such adjustment.



       
  ii.

Other Notices. If (A) the Corporation shall declare a dividend (or any other distribution in whatever form) on the Common shares, (B) the Corporation shall declare a special nonrecurring cash dividend on or a redemption of Common shares, (C) the Corporation shall authorize the granting to all holders of Common shares of rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any shareholders of the Corporation shall be required in connection with any reclassification of the Common shares, any business combination, amalgamation or plan of arrangement to which the Corporation is a party, any sale or transfer of all or substantially all of the assets or undertaking of the Corporation, of any compulsory share exchange whereby the Common shares are converted into other securities, cash or property or (E) the Corporation shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Corporation, then, in each case, the Corporation shall cause to be filed at each office or agency maintained for the purpose of conversion of Series I Non-Voting Convertible First Preferred shares, and shall cause to be delivered to each holder of Series I Non-Voting Convertible First Preferred shares at its last address as it shall appear upon the share register of the Corporation, at least 61 days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common shares of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, business combination, amalgamation, plan of arrangements, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common shares of record shall be entitled to exchange such shares for securities, cash or other property deliverable upon such reclassification, consolidation, business combination, amalgamation, plan of arrangements, sale, transfer or share exchange, provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice.


  (6)

Fractional shares:

     
 

No fractional Common shares shall be issued upon the conversion of Series I Non-Voting Convertible First Preferred shares. As to any fraction of a Common share which a holder would otherwise be entitled to receive upon such conversion, the Corporation shall at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Conversion Price or round up to the next whole Common share.



 4k

  (7)

Tax Election:

     
 

An election in prescribed form and within the prescribed time limit shall be made by the Corporation under subsection 191.2(1) of the Income Tax Act (Canada) with respect to the Series I Non-Voting Convertible First Preferred shares.




9.

The issue, transfer or ownership of shares is/is not restricted and the restrictions (if any) are as follows:

 

L’émission, le transfert ou la propriété d’actions est/n’est pas restreint. Les restrictions, s’il y a lieu, sont les suivantes :

     
 

None

     
  10.

Other provisions, (if any):
Autres dispositions s’il y a lieu :

     
 

None

     
11.

The statements required by subsection 178(2) of the Business Corporations Act are attached as Schedule ”A”.

 

Les déclarations exigées aux termes du paragraphe 178(2) de la Loi sur les sociétés par actions constituent l’annexe A.

     
  12.

A copy of the amalgamation agreement or directors’ resolutions (as the case may be) is/are attached as Schedule “B”.
Une copie de la convention de fusion ou les résolutions des administrateurs (selon le cas) constitue(nt) l’annexe B.

Page 5 of/de 6


These articles are signed in duplicate.
Les présents status sont signés en double exemplaire.

Name and original signature of a director or authorized signing officer of each of the amalgamating corporations. Include the name of each corporation, the signatories name and description of office (e.g. president, secretary). Only a director or authorized signing officer can sign on behalf of the corporation. / Nom et signature originale d’un administrateur ou d’un signataire autorisé de chaque société qui fusionne. Indiquer la dénomination sociale de chaque société, le nom du signataire et sa fonction (p. ex. : président, secrétaire). Seul un administrateur ou un dirigeant habilité peut signer au nom de la société.


  Stem Cell Therapeutics Corp.        
           
  Name of Corporations / Dénomination sociale des sociétés  
           
  By / Par   James Parsons   Chief Financial Officer
           
  (signed) « James Parsons »        
  Signature / Signature   Print name of signatory /   Description of Office / Fonction
      Nom du signataire en lettres moulées    
           
  Trillium Therapeutics Inc.        
           
  Name of Corporations / Dénomination sociale des sociétés        
           
  By / Par   James Parsons   Chief Financial Officer
           
  (signed) « James Parsons »        
  Signature / Signature   Print name of signatory /   Description of Office / Fonction
      Nom du signataire en lettres moulées    
             
             
  Name of Corporations / Dénomination sociale des sociétés  
           
  By / Par        
            
           
  Signature / Signature   Print name of signatory /   Description of Office / Fonction
       Nom du signataire en lettres moulées    
            
            
  Name of Corporations / Dénomination sociale des sociétés  
           
  By / Par        
            
           
  Signature / Signature   Print name of signatory /   Description of Office / Fonction
      Nom du signataire en lettres moulées    
           
           
  Name of Corporations / Dénomination sociale des sociétés  
           
  By / Par        
           
           
  Signature / Signature   Print name of signatory /   Description of Office / Fonction
      Nom du signataire en lettres moulées    

Page 6 of/de 6


SCHEDULE “A”

STATEMENT OF DIRECTOR OR OFFICER

1.

I am the Chief Financial Officer of Stem Cell Therapeutics Corp. (“Amalgamating Corporation 1”) and as such have knowledge of its affairs.

     
2.

I am the Chief Financial Officer of Trillium Therapeutics Inc. (“Amalgamating Corporation 2”) and as such have knowledge of its affairs.

     
3.

I have conducted such examinations of the books and records of Amalgamating Corporation 1 and of Amalgamating Corporation 2 and have made such enquiries and investigations as are necessary to enable me to make this statement.

     
4.

There are reasonable grounds for believing that:

     
(a)

each of the Amalgamating Corporations is and the corporation to be formed by their amalgamation (the “Amalgamated Corporation”) will be able to pay its liabilities as they become due;

     
(b)

the realizable value of the assets of the Amalgamated Corporation will not be less than the aggregate of its liabilities and stated capital of all classes; and

     
(c)

no creditor of the Amalgamating Corporation will be prejudiced by such amalgamation.

Dated as of the 27th day of May, 2014.

  (signed) “James Parsons
  James Parsons, Chief Financial Officer


SCHEDULE “B”

STEM CELL THERAPEUTICS CORP.
(the “Corporation”)

RESOLUTION OF THE DIRECTORS

Dated as of the 27th day of May, 2014.

RECITAL:

The Corporation wishes to amalgamate with its wholly-owned subsidiary, Trillium Therapeutics Inc. (the “Subsidiary”), under the Business Corporations Act (Ontario) (the “Act”).

RESOLVED that:

1.

the Corporation amalgamate with the Subsidiary and continue as one corporation (the “Amalgamated Corporation”) under subsection 177(1) of the Act effective June 1, 2014 or such other date as may be determined by any director or officer of the Corporation;

     
2.

except as may be prescribed, the articles of amalgamation of the Amalgamated Corporation be the same as the articles of the Corporation;

     
3.

the by-laws of the Amalgamated Corporation be the same as the by-laws of the Corporation;

     
4.

on the issuance of a Certificate of Amalgamation under subsection 178(4) of the Act:

     
(a)

all shares of the Subsidiary be cancelled without any repayment of capital;

     
(b)

no securities be issued and no assets be distributed by the Amalgamated Corporation in connection with the amalgamation; and

     
(c)

the stated capital of the Amalgamated Corporation be the same as the stated capital of the Corporation; and

     
5.

any director or officer of the Corporation is authorized and directed to do on behalf of the Corporation any and all acts and things and execute all documents as such director or officer considers necessary, desirable or useful to carry out and give effect to the amalgamation of the Corporation and the Subsidiary and to this resolution.

The undersigned certifies that the foregoing is a true and complete copy of a resolution of Stem Cell Therapeutics Corp. which was consented to by all the directors of the Corporation on the 27th day of May, 2014, and that the said resolution is in force and effect, unamended, at the date hereof.

Dated as of the 27th day of May, 2014. (signed) “James Parsons
  James Parsons, Chief Financial Officer


SCHEDULE “B”

TRILLIUM THERAPEUTICS INC.
(the “Corporation”)

RESOLUTION OF THE DIRECTORS

Dated as of the 27th day of May, 2014.

RECITAL:

The Corporation is a wholly-owned subsidiary of, and wishes to amalgamate with, Stem Cell Therapeutics Corp. (“Holdco”), under the Business Corporations Act (Ontario) (the “Act”).

RESOLVED that:

1.

the Corporation amalgamate with Holdco and continue as one corporation (the “Amalgamated Corporation”) under subsection 177(1) of the Act effective June 1, 2014 or such other date as may be determined by any director or officer of the Corporation;

     
2.

except as may be prescribed, the articles of amalgamation of the Amalgamated Corporation be the same as the articles of Holdco;

     
3.

the by-laws of the Amalgamated Corporation be the same as the by-laws of Holdco;

     
4.

on the issuance of a Certificate of Amalgamation under subsection 178(4) of the Act:

     
(a)

all shares of the Corporation be cancelled without any repayment of capital;

     
(b)

no securities be issued and no assets be distributed by the Amalgamated Corporation in connection with the amalgamation; and

     
(c)

the stated capital of the Amalgamated Corporation he the same as the stated capital of Holdco; and

     
5.

any director or officer of the Corporation is authorized and directed to do on behalf of the Corporation any and all acts and things and execute all documents as such director or officer considers necessary, desirable or useful to carry out and give effect to the amalgamation of the Corporation and Holdco and to this resolution.

The undersigned certifies that the foregoing is a true and complete copy of a resolution of Trillium Therapeutics Inc. which was consented to by all the directors of the Corporation on the 27th day of May, 2014, and that the said resolution is in force and effect, unamended, at the date hereof.

Dated as of the 27th day of May, 2014. (signed) “James Parsons
  James Parsons, Chief Financial Officer



Dates Referenced Herein

This ‘20FR12B’ Filing    Date    Other Filings
Filed on:8/12/14None on these Dates
6/1/14
 List all Filings


7 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/13/21  Trillium Therapeutics Inc.        10-Q        6/30/21   56:5.1M                                   Toppan Merrill Bridge/FA
 5/07/21  Trillium Therapeutics Inc.        10-Q        3/31/21   52:3.4M                                   Toppan Merrill/FA
 3/18/21  Trillium Therapeutics Inc.        10-K       12/31/20   87:8.2M                                   Toppan Merrill/FA
 1/09/15  SEC                               UPLOAD9/20/17    1:36K  Trillium Therapeutics Inc.
11/05/14  SEC                               UPLOAD9/20/17    1:133K Trillium Therapeutics Inc.
10/22/14  SEC                               UPLOAD9/20/17    1:139K Trillium Therapeutics Inc.
 9/09/14  SEC                               UPLOAD9/20/17    1:185K Trillium Therapeutics Inc.
Top
Filing Submission 0001062993-14-004759   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Wed., May 15, 6:45:20.2pm ET